Today NIH announced the launch of #ACTIV-2 (outpatient) Phase 2/3 and ACTIV-3 (inpatient) Phase 3 clinical trials investigating the use of monoclonal antibodies as a potential treatment for #COVID19. Antibodies are molecules our immune systems use to fight germs. People recovered from #COVID19 can produce antibodies. Researchers can examine blood samples from COVID-19 survivors & isolate antibodies. Scientists then create lab-engineered copies, thus making monoclonal antibodies. | National Insti

36K views · 138 reactions | Monoclonal antibody treatment may help reduce the risk of hospitalization and serious complications for eligible high-risk people who test positive for COVID-19. | ND Health and Human Services | Facebook

46 reactions · 12 shares | What is monoclonal antibody therapy? Learn more about how it works: https://stan.md/3ja9bO2 | Stanford Medicine | Facebook